EW STOCK FORECAST: After giving 40% returns to investors over 1 year, will the mometum continue in 2022?

EW Stock Forecast: For the Next 24 hours, the stock price of EW is predicted to trade between $ 115.94 and $ 122.70. The Overall recommendation for next 24 hours is buy.
2 of 3 momentum indicators are positive
EW is trading 2.13% higher at $ 122.12 in the last trading session.
Metric | Value |
Market Cap | 7.6 B |
Share Volume | 6M |
Average Share Volume | 2 M |
Forward PE (1year) | 52.91 |

EW Stock Forecast: Momentum Summary
Metric | Indicator |
Price | Higher |
Technical indicators | Buy |
Sentiment | NA |
EW Stock Forecast: Performance Chart
1 Day | 5 Days | 1 month | 1 year | |
EW Stock | 2.13% | 0.24% | 4.35% | 42.60% |
EW Stock Forecast: Technical Analysis
Analyst | S3 | R1 | Recommendation |
Investing.com | 114.52 | 121.76 | Buy |
Barchart.com | 117.37 | 123.65 | Buy |
EW Stock Forecast: Latest Videos
Edwards Lifesciences CEO on outlook for 2022: ‘We are just getting started’
EW Stock Forecast: Sentiment Analysis
Day | Positive | Negative | Indicator |
Day 7 | 0% | 6% | Negative |
Day 1 | NA | NA | NA |
Also Read: Moderna Stock Forecast
EW Stock Forecast: Latest News and Tweets
Ew Healthcare Partners Fund 2, Buys 5,050 Shares of TELA Bio, Inc. (NASDAQ:TELA) Stock
EW Stock Forecast: Company Background
Edward lifesciences is an American based medical technology company. It was founded in the year 1958 in Irvine, California. The company works on Artificial heart valves and hemodynamic monitoring and produces new technologies to treat late cardiovascular diseases. It was founded by an engineer Miles Lowell Edwards.
EW Stock Forecast: Q3 Results
- Sales increased 15% to 1.3 billion as of on 30th September
- Increased 15% in TAVR sales
- Increased in US TAVR sales by 12% and OUS approximately 20%
- Full year 2021 sales guidance range changed
- EW reported that TAVR sales are $858 million in this third quarter of the financial year
- With 7% increase compared to third quarter of the last year surgical structural heart sales were $217 million
- The adjusted gross profit margin was 76.3% compared to 75.5% in the third quarter of last financial year.
- Research and development expenses were $238 million by an increase of 22%
- Free cash flow was $471 million and cash flow from operating activities is $532 million
-Rakesh Atla
You must be logged in to post a comment.